TY - JOUR
T1 - Current status of the satisfaction levels of adult patients receiving drugs for atopic dermatitis and chronic urticaria
AU - Kaneko, Sakae
AU - Nakahara, Takeshi
AU - Sumikawa, Yasuyuki
AU - Fukunaga, Atsushi
AU - Masuda, Koji
AU - Kakamu, Takeyasu
AU - Morita, Eishin
N1 - Funding Information:
This study was partially supported by Collaborative Research Grants 2017‐2019 from the Japanese Society for Cutaneous Immunology and Allergy. We thank the research assistant in the Department of Dermatology of Shimane University for assisting with this study.
Publisher Copyright:
© 2021 The Authors. Journal of Cutaneous Immunology and Allergy published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society for Cutaneous Immunology and Allergy
PY - 2021
Y1 - 2021
N2 - Objectives: The satisfaction level of adult patients receiving drugs for atopic dermatitis and chronic urticaria is unclear. The objective of this multicenter study was to assess the satisfaction level of adult patients receiving treatment for allergic skin diseases, primarily atopic dermatitis and chronic urticaria. Methods: We developed a self-administered questionnaire with multiple-choice questions on patient characteristics, quality of life (QOL), and Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). We surveyed 302 patients receiving dermatological treatment. Results: The global satisfaction of patients (TSQM-9) was lower for atopic dermatitis treatment compared with that for chronic urticaria. For atopic dermatitis, dupilumab had higher scores for effectiveness and global satisfaction, whereas topical tacrolimus and moisturizers had higher scores for convenience. For chronic urticaria, omalizumab had higher scores for effectiveness and global satisfaction, while antihistamines had a higher score for convenience. The Dermatology Life Quality Index was significantly associated with treatment effectiveness and global satisfaction, and patient satisfaction improved with the corresponding improvement in the QOL. For atopic dermatitis, satisfaction with dupilumab was higher than that with conventional standard therapy, after the confounding factors were eliminated. However, the same trend was not observed for chronic spontaneous urticaria. Conclusions: The satisfaction of the effectiveness for the biologic agents was higher, compared to that with conventional standard therapy. Treatment with biologics is worth exploring for patients who are not satisfied with their existing treatments.
AB - Objectives: The satisfaction level of adult patients receiving drugs for atopic dermatitis and chronic urticaria is unclear. The objective of this multicenter study was to assess the satisfaction level of adult patients receiving treatment for allergic skin diseases, primarily atopic dermatitis and chronic urticaria. Methods: We developed a self-administered questionnaire with multiple-choice questions on patient characteristics, quality of life (QOL), and Abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). We surveyed 302 patients receiving dermatological treatment. Results: The global satisfaction of patients (TSQM-9) was lower for atopic dermatitis treatment compared with that for chronic urticaria. For atopic dermatitis, dupilumab had higher scores for effectiveness and global satisfaction, whereas topical tacrolimus and moisturizers had higher scores for convenience. For chronic urticaria, omalizumab had higher scores for effectiveness and global satisfaction, while antihistamines had a higher score for convenience. The Dermatology Life Quality Index was significantly associated with treatment effectiveness and global satisfaction, and patient satisfaction improved with the corresponding improvement in the QOL. For atopic dermatitis, satisfaction with dupilumab was higher than that with conventional standard therapy, after the confounding factors were eliminated. However, the same trend was not observed for chronic spontaneous urticaria. Conclusions: The satisfaction of the effectiveness for the biologic agents was higher, compared to that with conventional standard therapy. Treatment with biologics is worth exploring for patients who are not satisfied with their existing treatments.
UR - http://www.scopus.com/inward/record.url?scp=85112446282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112446282&partnerID=8YFLogxK
U2 - 10.1002/cia2.12200
DO - 10.1002/cia2.12200
M3 - Article
AN - SCOPUS:85112446282
JO - Journal of Cutaneous Immunology and Allergy
JF - Journal of Cutaneous Immunology and Allergy
SN - 2574-4593
ER -